314 related articles for article (PubMed ID: 17150101)
1. Gene expression patterns associated with p53 status in breast cancer.
Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM
BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101
[TBL] [Abstract][Full Text] [Related]
2. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
[TBL] [Abstract][Full Text] [Related]
4. Cell-type-specific responses to chemotherapeutics in breast cancer.
Troester MA; Hoadley KA; Sørlie T; Herbert BS; Børresen-Dale AL; Lønning PE; Shay JW; Kaufmann WK; Perou CM
Cancer Res; 2004 Jun; 64(12):4218-26. PubMed ID: 15205334
[TBL] [Abstract][Full Text] [Related]
5. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
[TBL] [Abstract][Full Text] [Related]
6. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
[TBL] [Abstract][Full Text] [Related]
7. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
8. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
[TBL] [Abstract][Full Text] [Related]
9. EGFR associated expression profiles vary with breast tumor subtype.
Hoadley KA; Weigman VJ; Fan C; Sawyer LR; He X; Troester MA; Sartor CI; Rieger-House T; Bernard PS; Carey LA; Perou CM
BMC Genomics; 2007 Jul; 8():258. PubMed ID: 17663798
[TBL] [Abstract][Full Text] [Related]
10. FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target.
Horton JK; Siamakpour-Reihani S; Lee CT; Zhou Y; Chen W; Geradts J; Fels DR; Hoang P; Ashcraft KA; Groth J; Kung HN; Dewhirst MW; Chi JT
Radiat Res; 2015 Nov; 184(5):456-69. PubMed ID: 26488758
[TBL] [Abstract][Full Text] [Related]
11. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
12. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
[TBL] [Abstract][Full Text] [Related]
13. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
14. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.
Wilson KS; Roberts H; Leek R; Harris AL; Geradts J
Am J Pathol; 2002 Oct; 161(4):1171-85. PubMed ID: 12368191
[TBL] [Abstract][Full Text] [Related]
15. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M; Elstrodt F; Klijn JG; Berns EM; Schutte M
Breast Cancer Res Treat; 2006 Sep; 99(1):97-101. PubMed ID: 16541312
[TBL] [Abstract][Full Text] [Related]
16. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
17. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network
Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
[TBL] [Abstract][Full Text] [Related]
19. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
Yu K; Ganesan K; Miller LD; Tan P
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3288-96. PubMed ID: 16740749
[TBL] [Abstract][Full Text] [Related]
20. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
